Immune checkpoint inhibitors have changed cancer treatment — but toxicity, resistance, and the lack of reliable predictive biomarkers continue to limit their impact. This landmark position paper by Hajjar et al. in #JIPO spans 93 pages, 50+ contributing authors from valued institutions like MD Anderson, and takes a comprehensive look at both where the field stands as well as where it needs to go.
doi.org/10.36401/JIPO-26-12
@HajjarJoud @BettzyStephen @ajaysheshadri @kjazieh @ANaingMD @OncologyNetwork
#PositionPaper #ICItherapy #irAEs #immunotherapy #precisiononcology #biomarkers #cancerresearch #JIPO
♧ 0 ⟳ 0 ♡ 1 ▤ 64